Business Context and Reporting Period
This Form 8-K Current Report for Xtant Medical Holdings, Inc. (XTNT) covers events occurring on August 1, 2025. The filing primarily addresses significant changes to the Company's Board of Directors, including the election of two new directors and the resignation of two existing directors, following a recent change in majority ownership.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and related transactional history.
Material Changes
- Board Composition Changes: On August 1, 2025, Abhinav (Abi) Jain and Tyler Lipschultz were elected to the Board of Directors, effective immediately. Concurrently, Robert McNamara and Lori Mitchell-Keller resigned from the Board.
- Committee Appointments: Mr. Jain was appointed to the Compensation Committee and Nominating and Corporate Governance Committee. Mr. Lipschultz was appointed to the Audit Committee and Compensation Committee.
- Ownership Context: The board changes follow a stock purchase agreement dated April 10, 2025, where Nantahala Capital Management, LLC (an affiliate of Mr. Jain) purchased 57 million shares, becoming the beneficial owner of 49.1% of the Company's outstanding common stock.
Outlook, Risks, and Management Commentary
Management Commentary: The Board determined that the new composition is in the best interests of the Company and its stockholders. The resignations of Mr. McNamara and Ms. Mitchell-Keller were not due to any disagreement with the Company regarding operations, policies, or practices, but were pursuant to an oral understanding with Nantahala regarding board composition.
Compensation and Agreements: The new directors will receive customary non-employee director compensation and have entered into standard indemnification agreements with the Company.
Risks and Contingencies: The filing notes no other arrangements or understandings between the new directors and other persons regarding their selection. There are no arrangements between the Company and Nantahala regarding board composition or other governance rights beyond the disclosed changes.
Investor Verification Checklist
- Verify the beneficial ownership percentage of Nantahala Capital Management, LLC (stated as 49.1%) and its influence on future corporate strategy.
- Review the definitive proxy statement for the Annual Meeting held on July 23, 2024, to understand the specific compensation structure for the new directors.
- Confirm the status of the shelf resale registration statement filed on May 12, 2025, which became effective on May 19, 2025, to facilitate the sale of shares by the OrbiMed Sellers.
- Assess the strategic fit of Mr. Lipschultz's 35+ years of experience in orthopaedics and biologics relative to Xtant's current product portfolio.